Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Added Value of 166Ho Trans-arterial Radioembolization to Systemic Therapy in Liver Metastatic Breast Cancer Patients

NCT06142344 is registered in ClinicalTrials.gov with The Netherlands Cancer Institute as lead sponsor.

NCT NCT06142344
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06142344 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Added Value of 166Ho Trans-arterial Radioembolization to Systemic Therapy in Liver Metastatic Breast Cancer Patients
Lead sponsor
The Netherlands Cancer Institute
Phase
Not applicable
Overall status
Unknown status
Start date
October 19, 2023
Completion date
January 19, 2026
Enrollment
13 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, liver metastases